Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 1998, p. 2530-2534, Vol. 36, No. 9
Max von Pettenkofer-Institute for Hygiene and
Medical Microbiology1 and
Department of
Surgery, Clinic Innenstadt,2 Ludwig
Maximilians University Munich, 80336 Munich, Germany
Received 12 March 1998/Returned for modification 14 May
1998/Accepted 28 May 1998
From two different specimens of a chronic prosthetic hip infection
taken at an interval of 2 months a slow-growing gram-negative bacterium
was isolated in pure culture. The strain grew with the typical features
of a small-colony variant (SCV). 16S rRNA sequencing identified the
bacterium as Escherichia coli. Biochemical characterization demonstrated multiple phenotypic alterations of a mutant carrying a
defect in the heme biosynthetic pathway (Hem The term "small colony variant"
(SCV) refers to the phenomenon where certain variants of bacteria grow
slowly on routine media and yield unexpectedly small colonies in
comparison to the normally growing parent strains (for a review see
reference 28). The phenomenon of SCVs has been known
since the beginning of this century (17) and has been
reported for many genera and species, including the genera
Staphylococcus and Pseudomonas and diverse enterobacteriaceae species (1, 5, 7, 9, 18, 31-33, 37). So
far, nearly all SCVs isolated from clinical specimens have been
identified as Staphylococcus aureus and were most commonly associated with persistent and relapsing infections (1, 16, 29,
35). SCVs of other genera isolated from clinical materials have
been reported only rarely and were not well characterized (15, 25,
31). The largest number of studies concerning SCVs are available
for S. aureus.
Some characteristic features that are often but not always found in
SCVs have been described: (i) auxotrophy (e.g., for hemin, menadione,
or thiamine) (1, 28, 33, 38), (ii) decreased respiration
(20, 21), (iii) resistance to aminoglycoside antibiotics (3, 27, 36, 38), (iv) limited fermentation of sugars (10, 20, 21, 39), and (v) the ability to revert to normal growth (1, 10, 21, 27). There are no data available about the genetic events responsible for the reappearance of larger colonies.
Therefore, in the context of SCV the term "revertants" refers only
to changes in the size of the colonies and does not imply actual
genetic reversion.
In vitro and in vivo exposure to aminoglycosides at or above the MIC
results in selection of SCVs in many genera (1, 18, 26, 27).
Slow growth, atypical colony morphology, altered biochemical profile,
and morphological instability may lead to failure in identification of
SCV strains in clinical laboratories. Inactivation of the heme
biosynthetic pathway (Hem In the present report we characterize a SCV of E. coli
isolated from a relapsing prosthetic hip infection. This strain carries a mutation in the heme biosynthetic pathway and accordingly shows multiple phenotypic changes. To our knowledge, this is the first description of a SCV E. coli strain as the etiological agent
of a chronic infection.
A 62-year-old woman who had undergone two previous arthroplasties
of her left hip presented at a surgical outpatient department in May
1997 with a small, red, swollen abscess which had developed over a
period of 5 weeks in the scar area of her left hip after implantation
of a third endoprosthesis in October 1995. There were no signs of
systemic disease. The axillar temperature was 36.9°C. A blood count
showed slight leukopenia (3.9 × 109/liter). Upon
sonographic examination of her hip, the abscess ruptured and a purulent
bloody fluid was spontaneously discharged. On microbiological analysis
of the abscess material, a slow-growing gram-negative bacterium was
isolated in pure culture (the first isolation of Z-2376).
Radiologically, a fistula was shown connecting the abscess with the
bone cavity of the implanted prosthesis. After admission, the fistula
was surgically revised and drained, since the patient refused
implantation of a new prosthesis. Pathological examination of the
excised fistula showed a chronic granulomatous and fibrosing
inflammation. Two weeks later, the patient was discharged home after
clinical improvement following empirical intravenous treatment with
cefuroxime, which was later changed to oral ofloxacin. In the following
4 weeks, a new abscess developed, which had to be opened and drained
surgically after rehospitalization. Intraoperatively obtained swab
material again produced slow-growing gram-negative organisms (the
second isolation of Z-2376). After 2 weeks, the patient was discharged
with only a slightly secreting fistula, which was treated by draining
the wound repeatedly on an outpatient basis. Antibiotic treatment with
ofloxacin was discontinued after 6 weeks. Four months later, the
fistula showed no signs of infection. Swabs were taken from the
fistula, yielding no bacterial growth, and a serum specimen was
obtained. The patient's past medical history included two previous
implantations of total endoprostheses in 1984 and 1994. Five days after
the second implantation, the prosthesis had to be removed due to an
infection with Proteus mirabilis diagnosed in a peripheral
laboratory. Reimplantation at that time was refused and postponed until
October 1995, when the currently infected third prosthesis was
implanted. It is noteworthy that gentamicin was not used as pre- or
postsurgical prophylaxis in any of the three hip arthroplasties.
Bacteria and culture conditions.
E. coli Z-2376 was
obtained from two different specimens of the scar area of a patient
with a prosthetic hip infection. E. coli DH5 Biochemical reactions and motility testing.
The tests for
catalase, nitrate reductase, and motility were performed by standard
procedures. For the catalase reaction, a colony was dipped on a glass
slide and overlaid with 3% H2O2. The
appearance of bubbles indicates a positive test result. Motility was
tested in a hanging-drop chamber and in motility-soft agar. For
biochemical characterization, bacteria were grown in brain heart
infusion (BHI; Oxoid, Unipath Ltd.) with or without 20 µg of hemin/ml
for 24 h. Bacteria were harvested by centrifugation and identified
with an API 20 E system (bio-Merieux Ltd., Marcy l'Etoile, France).
The benzidine test for detection of peroxidase activity of heme
proteins and heme cytochromes was performed with benzidine
hydrochloride (Sigma-Aldrich) and H2O2 as
described previously (12).
Determination of the reversion frequency of the SCV.
To
determine the reversion frequency, single small colonies grown on blood
agar plates for 48 h were resuspended in phosphate-buffered saline
(PBS). Serial dilutions of these suspensions were plated on blood agar
plates and incubated at 37°C. After 48 h small and large
colonies were counted. The test was performed in duplicate and repeated
three times.
Gentamicin resistance.
The MIC of gentamicin was determined
for small and large colonies with E-test strips (VIVA Diagnostika GmbH,
Cologne, Germany) on blood agar plates (8). McFarland
standard 0.5 inoculum was used. The plates were incubated at 37°C
under aerobic conditions for 48 h.
Antibody detection.
Cell lysates from bacteria grown under
different conditions were separated by sodium dodecyl sulfate-11%
polyacrylamide gel electrophoresis, transferred to nitrocellulose
sheets (BA85; Schleicher and Schüll, Inc.), and incubated with
sera diluted in PBS buffer. The serum of the patient was used at a
dilution of 1:500. Pooled sera from 10 healthy volunteers diluted 1:100
served as a control. Subsequently, the binding of immunoglobulin G was
visualized by anti-immunoglobulin G-alkaline phosphatase conjugate
(Sigma-Aldrich) as described elsewhere (30).
16S rRNA gene sequence analysis.
Amplification and direct
sequencing of the gene encoding 16S rRNA was done as described
previously (13). Universal primers corresponding to the
E. coli rRNA gene from bp 8 to 28 and bp 1542 to 1522 were
used for PCR amplification. Amplicon contamination controls were
performed in parallel. The hypervariable regions V1 and V2 were
sequenced with a primer corresponding to bp 361 to 341. For solid-phase
DNA sequencing one of the oligonucleotides was biotinylated at the 5'
end. Dynabeads (DYNAL GmbH, Hamburg, Germany) were used for the
preparation of single-stranded DNA as recommended by the manufacturer.
Sequence data were compared with the EMBL GenBank (HUSAR-DKFZ,
Heidelberg, Germany).
PCR amplification of hemB and hemD and
generation of digoxigenin-labelled DNA probes.
For amplification
of the E. coli hemB gene (GenBank accession no. L44595), we
used four primers corresponding to the indicated base pairs of the
hemB gene: hemB1, 5'-GGCAGACCATGACAGACTTAAT-3' (bp
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Chronic Prosthetic Hip Infection Caused by a
Small-Colony Variant of Escherichia coli
![]()
ABSTRACT
Top
Abstract
Introduction
Case Report
Materials & Methods
Results
Discussion
References
): (i)
catalase and nitrate reductase reactions were both negative, (ii) a
negative benzidine reaction demonstrated the lack of heme-containing cytochromes, and (iii) growth stimulation under anaerobic conditions as
well as gentamicin resistance indicated defective aerobic respiration. PCR and Southern hybridization demonstrated that the mutation of the
SCV of E. coli was localized in the hemB gene
and was most likely due to a deletion of the hemB gene. On
blood agar plates revertants were recognized growing as normal-sized
colonies between the dominant small colonies of the strain. Feeding
experiments indicated that the revertants but not the small colonies
were permeable for hemin. A strong antibody response against the
infecting SCV of E. coli was found. To our knowledge, this
is the first report of a Hem
E. coli strain
as the etiological agent of a chronic bacterial infection.
![]()
INTRODUCTION
Top
Abstract
Introduction
Case Report
Materials & Methods
Results
Discussion
References
) is one possible cause for the
appearance of SCVs (7, 21, 24, 34, 38). Hemes are key
components of the electron transfer apparatus and the prosthetic groups
in different enzymes. The enzymes for heme biosynthesis and their
encoding genes (hemA to hemH and hemL)
are known in Escherichia coli (6). Mutation in
one of these genes resulted in cytochrome oxidase-, catalase-, and
nitrate reductase-negative strains which grew slowly under aerobic
conditions (21). Most E. coli strains are unable
to take up heme (6, 32).
![]()
CASE REPORT
Top
Abstract
Introduction
Case Report
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Case Report
Materials & Methods
Results
Discussion
References
was
purchased from Gibco-BRL (Eggenstein, Germany). Unless otherwise
stated, bacteria were cultured on Trypticase soy agar (TSA; Oxoid,
Unipath Ltd., Basingstoke, England) supplemented with 7% defibrinated
sheep blood (Oxoid, Unipath Ltd.) for 48 h at 37°C under aerobic
conditions. The sizes of the colonies were determined by plate
microscopy. Auxotrophy for hemin or
-aminolevulinic acid (
-ALA)
was tested by incubating bacteria on hemin- or
-ALA-supplemented TSA
for 48 h at 37°C under aerobic conditions. Hemin (Sigma-Aldrich Chemie GmbH, Deisenhofen, Germany) dissolved in 10% Tween 80 was used
at a final concentration of 20 µg/ml, and
-ALA (Sigma-Aldrich) was
used at a final concentration of 50 µg/ml. In addition, hemin permeability was tested on McConkey agar (Merck, Darmstadt, Germany) at
37°C under aerobic conditions by adding X-factor discs (Oxoid, Unipath Ltd.).
8 to 14); hemB2, 5'-ACCTGCAGCAGCTGCAACCA-3' (bp
565 to 546); hemB3, 5'-ACGGCCAGGTACAGGCGATT-3' (bp 597 to
616); and hemB4, 5'-CGCAGAATCTTCTTCTCAGCCA-3' (bp 1062 to
1041). For amplification of the E. coli hemD gene (GenBank
accession no. X12614), primer hemD1, 5'-CCGCTGGAGAAGAGTTAGTGA-3',
corresponding to bp 38 to 59, and primer hemD2,
5'-GACGACCAATAGTCGACAGTG-3', corresponding to bp 642 to 621 of the gene, were used. The oligonucleotides were synthesized by Roth
(Karlsruhe, Germany). PCR buffer, Taq DNA polymerase, and
the model 2400 DNA thermal cycler were obtained from Perkin-Elmer Cetus
(Foster City, Calif.); deoxynucleoside triphosphates were purchased
from Pharmacia LKB (Uppsala, Sweden). DNAs from different E. coli strains grown for 24 h in BHI were released by repeated
freezing and thawing and used as templates. The PCR reactions were
performed for 30 cycles with a profile of 94°C for 10 s, 58°C
for 60 s, and 72°C for 180 s. The PCR products were
analyzed on a 1.5% ethidium bromide-stained agarose gel.
with primer pairs hemB3
and -4 and hemD1 and -2, respectively, according to the method
described by Lion and Haas (22). Labelled PCR products were
purified in a 2% low-melting-point agarose gel (Roth) and denatured by
heat before being used as gene probes.
Preparation of genomic DNA, Southern blotting, and filter
hybridization.
Preparation of genomic DNA, Southern blotting, and
filter hybridization were done by standard procedures as described
previously (2). Small- and large-colony types of Z-2376 and
E. coli DH5
were each grown overnight in 10 ml of BHI.
Genomic DNAs were extracted with proteinase K (Boehringer, Mannheim,
Germany) and phenol (Roth). DNA (5 µg) from each strain was digested
with EcoRI (Boehringer). In duplicates, the DNA fragments
were separated on 0.7% agarose gels and transferred to nylon membranes
(Zeta probe; Bio-Rad, Richmond, Calif.) by vacuum blotting (Vacu gene;
Pharmacia). One nylon membrane was hybridized against the
hemB probe, and the other was hybridized against the
hemD probe at 68°C. Detection of hybrid DNA was carried
out by an enzyme immunoassay with anti-digoxigenin antibodies
conjugated to alkaline phosphatase (Boehringer) according to the
manufacturer's protocol.
| |
RESULTS |
|---|
|
|
|---|
Isolation and identification of a SCV of E. coli. Two specimens from the wound area of a patient suffering from chronic prosthetic hip infection were sent to our laboratory. From abscess material (first specimen) and a swab taken intraoperatively 2 months later (second specimen) we isolated a slow-growing gram-negative bacterium in pure culture. All tests performed for growth behavior and differentiation showed the same results for both isolates, and the bacterium was denoted with the laboratory accession number, Z-2376. On blood agar plates the diameters of the colonies of Z-2376 measured less than 0.1 mm after 24 h of aerobic incubation. After 48 h the colony size increased to about 0.2 mm, and some larger colonies 2 mm in diameter appeared. After 48 h of anaerobic incubation both colony types grew with identical morphologies as normal-sized colonies 1.2 mm in diameter. Z-2376 was cytochrome c oxidase negative and glucose fermentation positive. Repeated subcultures on different agar plates revealed that the larger colonies were revertants of the small ones and, remarkably, the larger colonies were only present on culture media containing blood. The biochemical characterization of the small colonies and the revertants with the API system did not facilitate an acceptable identification (low discrimination between E. coli and Enterobacter spp.). Sequencing of 16S rRNA was performed with the two colony types of both isolates of Z-2376, and in all four cases it showed identical sequences matching 100% with the 16S rRNA gene of E. coli. Thus, Z-2376 represented E. coli growing as a SCV.
Instability of the SCV.
To determine the reversion frequency
of the SCV, we resuspended 48-h-old small colonies in PBS and plated
serial dilutions on blood agar plates. After 48 h of incubation
large and small colonies were counted. The reversion frequency was
2 × 10
3 (standard deviation, ±0.5).
Characterization of E. coli Z-2376 as a
Hem
mutant.
Normal-sized colonies after anaerobic
incubation of SCVs resembled respiration-deficient (Res
)
bacteria (21). Therefore, we tested the small colonies and the revertants for other characteristics of Res
mutants,
such as (i) aminoglycoside resistance, (ii) negative benzidine
reaction, (iii) negative catalase reaction, and (iv) negative nitrate
reductase reaction. The small colonies were resistant to gentamicin
(MIC, 16 µg/ml), and the reactions for benzidine, catalase, and
nitrate reductase were all negative. In contrast, the revertants were
susceptible to gentamicin (MIC, 1.2 µg/ml), and the benzidine,
catalase, and nitrate reductase reactions were all positive.
-ALA, a precursor of hemin biosynthesis, failed to
promote growth of the small-colony type.
|
Detection of a mutated hemB gene in E. coli
Z-2376.
Lewis et al. reported that in Res
E. coli strains the hemB gene is a hot spot for
spontaneous mutations (21). We first tested the integrity of
the hemB gene in both colony types of Z-2376 by PCR
amplification of (i) the 5' half of the hemB gene (primers hemB1 and -2), (ii) the 3' half of the hemB gene (primers
hemB3 and -4), and (iii) a part of the hemD gene (primers
hemD1 and -2) as a control. All three PCRs resulted in PCR products of
the correct size for E. coli DH5
. The small-colony type
and the revertant of Z-2376, however, showed correct PCR products only
for the hemD PCR. The PCRs for the hemB gene
resulted in nonspecific or no amplification (data not shown). For
further characterization we generated two digoxigenin-labelled DNA
probes, one for the hemB gene of E. coli and the
other for the hemD gene of E. coli. Both probes
were hybridized against identical nylon membranes carrying immobilized
genomic DNAs of both colony types of Z-2376 and E. coli
DH5
. The Southern blot is shown in Fig.
2. In contrast to the hemD
gene, which was present in all three strains,
hemB-homologous sequences could not be detected in either
colony type of Z-2376. This result demonstrates that the
hemB gene in Z-2376 is inactivated by a deletion of part of
the gene or the whole gene.
|
Demonstration of E. coli-specific antibodies. Persistent infections should result in the production of specific antibodies against the bacterial agents. We tested the serum of the patient by immunoblotting for the presence of antibodies against Z-2376. To induce different antigens, small and large colonies of Z-2376 were incubated under aerobic and anaerobic conditions on TSA-blood agar plates and whole-cell lysates for immunoblotting were prepared. Pooled sera from healthy volunteers served as a negative control. A strong antibody response against Z-2376 could be detected in the serum of the patient but not in the control sera (Fig. 3).
|
| |
DISCUSSION |
|---|
|
|
|---|
Persistent bacterial infections are typically due to slow-growing microorganisms, e.g., Mycobacteria, Borrelia, or Helicobacter spp., whereas fast-growing bacteria like S. aureus or E. coli most often cause acute, purulent infections. Nevertheless, chronic infections have also been reported for S. aureus which could often be correlated with the appearance of SCVs (1, 16, 29, 35). Mutations in biosynthetic pathways resulting in a decreased growth rate of the pathogen obviously could influence the course of infections. This phenomenon, described for S. aureus, might occur in other bacteria as well.
In the present study, we describe a SCV of E. coli as the etiological agent of a recurrent prosthetic hip infection. Our patient had a history of three prosthetic hip replacements in the last 15 years, with one episode of acute prosthetic hip infection 3 years ago. From two different specimens of the infected hip taken at an interval of 2 months we isolated a slow-growing gram-negative bacterium in pure culture that was identified as E. coli by 16S rRNA sequencing. As a consequence of the chronic infection, the patient had developed large amounts of antibodies against the E. coli strain, as demonstrated by immunoblotting. This immune response, however, was obviously not effective in eliminating the pathogen.
The growth characteristics of E. coli Z-2376 under aerobic
and anaerobic conditions as well as its gentamicin resistance
resembled those of a SCV. Further characterization of the
clinical isolate demonstrated the phenotypic alterations of
Hem
E. coli strains. Heme is a prosthetic
group of respiratory cytochromes and several other enzymes involved in
energy metabolism and oxidative catalysis (6). Mutations in
the biosynthesis of heme result in cytochrome oxidase-negative,
catalase- and peroxidase-negative, and nitrate reductase-negative
strains. As a consequence, these strains are slow growing under aerobic
conditions and appear as SCVs (7, 21, 24, 32).
Lewis et al. demonstrated by in vitro selection for
respiratory-deficient E. coli strains that 80% of these
mutants carried the defect in the hemB gene (21).
Deletions or insertions of the transposable element IS2 were
responsible for the inactivation (19). Using PCR and
Southern hybridization, we tested the integrity of the hemB
gene in Z-2376. Both techniques were unable to detect hemB-homologous sequences in Z-2376, demonstrating that a
deletion of part or all of the hemB gene is responsible for
the Hem
phenotype of Z-2376. hemB mutants do
not respond to
-ALA, the precursor of heme biosynthesis. Likewise,
the growth of E. coli Z-2376 could not be stimulated with
-ALA.
It is well known that E. coli is usually impermeable for
hemin and that Hem
E. coli strains cannot
utilize supplemented hemin (6, 34). In
Hem
E. coli strains, however, revertants
have been recognized that respond to hemin supplementation and grow as
normal-sized colonies on hemin-containing agar plates (7,
23). E. coli Z-2376 showed exactly the same
phenomenon. With a remarkably constant frequency of 2 × 10
3, hemin-permeable revertants grew as large colonies on
blood- or hemin-containing agar plates. As shown by PCR and Southern hybridization, these revertants carried the same deletion in the hemB gene as did the small colonies of Z-2376.
Based on the data presented above, there is evidence for at least two
independent mutations in E. coli Z-2376: (i) the first mutation is located in the heme biosynthesis genes (deletion of hemB), resulting in slow growth and the appearance of SCVs;
(ii) the second event occurs in the SCVs with a frequency of 2 × 10
3 and results in hemin permeability of the SCV.
Correlation of the two different mutations with the course of the
infection is hypothetical; the first mutation slowed the growth rate of
the bacterium, resulting in SCVs and persistance, while the second mutation accelerated the growth rate of the SCVs and resulted in
reactivation of the infection.
Three years ago, the patient suffered from an infection of her prosthetic hip following immediately after the second implantation. A sole microorganism, P. mirabilis, had been isolated. After explantation, the scar area was rinsed with a disinfectant (Lavasept) and the patient was treated with cefuroxime. P. mirabilis is a rare and unusual cause of wound infection after surgical intervention, particularly in joints. However, it might be that P. mirabilis was not the only gram-negative rod that gained access to the wound area. The presence of concomitant bacteria, such as E. coli, could have been masked in the diagnostic laboratory by the swarming motility of Proteus spp. On the other hand, we cannot exclude the possibility that E. coli might have infected the joint on a different occasion or from the bloodstream as a result of bacteremia.
Antibiotic treatment with aminoglycosides, which are known to select SCVs, was not reported in the patient's history as pre- or postsurgical prophylaxis in any of the three hip arthroplasties. Therefore, other, yet-unknown factors might have been involved in generation of the SCVs.
How should infections with the E. coli SCV be treated with antibiotics? In general, standardized antimicrobial susceptibility testing and correlation between such testing and successful treatment are not known for infections with the E. coli SCV. However, the presumed pathogenesis of infections with SCVs should be considered in treatment. SCVs are thought to persist intracellularly in a quiescent metabolic state inside the host (29). For eradication of persistent infections only bactericidal antibiotics are promising. Eng et al. (14) demonstrated that fluoroquinolones exhibit the highest activity against slow-growing and nongrowing bacteria. Moreover, fluoroquinolones show high intracellular activity (4, 11). The patient described in this study was treated with a fluoroquinolone derivate for 6 weeks. Six months later the fistula still persisted. Swabs taken from deep within the fistula yielded no bacterial growth. However, it remains questionable whether the patient had overcome the infection with the SCV of E. coli.
In routine laboratory testing, the presence of SCV in clinical specimens is difficult to verify. Colony formation by SCVs can often be detected only after more than 48 h of culture during primary isolation. Moreover, atypical growth behavior and unusual biochemical reactions (in this case, no growth on McConkey agar and negative catalase, nitrate reductase, and indole reactions, respectively) may result in misidentification of the microorganism. Therefore, it is most important to take SCVs into account as a possible cause of persistent infectious diseases, particularly when no bacteria or unusual bacteria are found in materials obtained in such cases.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Max von Pettenkofer-Institute for Hygiene and Medical Microbiology, Ludwig Maximilians University Munich, Pettenkoferstr. 9a, 80336 Munich, Germany. Phone: 49-89-51605200. Fax: 49-89-5380584. E-mail: rogge{at}m3401.mpk.med.uni-muenchen.de.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Acar, J. F.,
F. W. Goldstein, and P. Lagrange.
1978.
Human infections caused by thiamine- or menadione-requiring Staphylococcus aureus.
J. Clin. Microbiol.
8:142-147 |
| 2. | Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1989. Current protocols in molecular biology. John Wiley & Sons, New York, N.Y. |
| 3. | Balwit, J. M., P. van Langevelde, J. M. Vann, and R. A. Proctor. 1994. Gentamicin-resistant menadione and hemin auxotrophic Staphylococcus aureus persist within cultured endothelial cells. J. Infect. Dis. 170:1033-1037[Medline]. |
| 4. | Barza, M. 1994. Challenges to antibiotic activity in tissue. Clin. Infect. Dis. 19:910-915[Medline]. |
| 5. |
Bayer, A. S.,
D. C. Norman, and K. S. Kim.
1987.
Characterization of impermeability variants of Pseudomonas aeruginosa isolated during unsuccessful therapy of experimental endocarditis.
Antimicrob. Agents Chemother.
31:70-75 |
| 6. | Beale, S. I. 1996. Biosynthesis of heme, p. 731-748. In F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C. |
| 7. | Beljanski, M., and M. Beljanski. 1957. Sur la formation d'enzymes respiratoires chez un mutant d'Escherichia coli streptomycine-resistant et auxotrophe pour l'hèmine. Ann. Inst. Pasteur 92:396-412[Medline]. |
| 8. | Bolmstrom, A. 1994. Determinations of minimal bactericidal concentrations, kill curves, and postantibiotic effects with the Etest technology. Diagn. Microbiol. Infect. Dis. 19:187-195[Medline]. |
| 9. |
Bryan, L. E., and S. Kwan.
1981.
Aminoglycoside-resistant mutants of Pseudomonas aeruginosa deficient in cytochrome d, nitrite reductase, and aerobic transport.
Antimicrob. Agents Chemother.
19:958-964 |
| 10. | Chinn, B. D. 1936. Characteristics of small colony variants with special reference to Shigella paradysenteriae sonne. J. Infect. Dis. 59:137-151. |
| 11. |
Darouiche, R. O., and R. J. Hamill.
1994.
Antibiotic penetration of and bactericidal activity within endothelial cells.
Antimicrob. Agents Chemother.
38:1059-1064 |
| 12. |
Deibel, R. H., and J. B. Evans.
1960.
Modified benzidine test for the detection of cytochrome-containing respiratory systems in microorganisms.
J. Bacteriol.
79:356-360 |
| 13. |
Edwards, U.,
T. Rogall,
H. Blöcker,
M. Emde, and E. C. Böttger.
1989.
Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S rRNA.
Nucleic Acids Res.
17:7843-7852 |
| 14. |
Eng, R. H.,
F. T. Padberg,
S. M. Smith,
E. N. Tan, and C. E. Cherubin.
1991.
Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria.
Antimicrob. Agents Chemother.
35:1824-1828 |
| 15. |
Funada, H.,
K. I. Hattori, and N. Kosakai.
1978.
Catalase-negative Escherichia coli isolated from blood.
J. Clin. Microbiol.
7:474-478 |
| 16. | Goudie, J. G., and R. B. Goudie. 1998. Recurrent infection by a stable dwarf-colony variant of Staphylococcus aureus. J. Clin. Pathol. 8:284-287. |
| 17. | Kolle, W., and H. Hetsch. 1911. Die experimentelle Bakteriologie und die Infektionskrankheiten mit besonderer Berücksichtigung der Immunitätslehre. Urban und Schwarzenberg, Berlin, Germany. |
| 18. | Lacey, R. W. 1969. Dwarf-colony variants of Staphylococcus aureus resistant to aminoglucoside antibiotics and to a fatty acid. J. Med. Microbiol. 2:187-197[Medline]. |
| 19. |
Lewis, L. A.,
D. Lewis,
V. Persaud,
S. Gopaul, and B. Turner.
1994.
Transposition of IS2 into the hemB gene of Escherichia coli K-12.
J. Bacteriol.
176:2114-2120 |
| 20. |
Lewis, L. A.,
K. Li,
M. Bharosay,
M. Cannella,
V. Jorgenson,
R. Thomas,
D. Pena,
M. Velez,
B. Pereira, and A. Sassine.
1990.
Characterization of gentamicin-resistant respiratory-deficient (res ) variant strains of Staphylococcus aureus.
Microbiol. Immunol.
34:587-605[Medline].
|
| 21. |
Lewis, L. A.,
K. B. Li,
A. Gousse,
F. Pereira,
N. Pacheco,
S. Pierre,
P. Kodaman, and S. Lawson.
1991.
Genetic and molecular analysis of spontaneous respiratory deficient (res ) mutants of Escherichia coli K-12.
Microbiol. Immunol.
35:289-301[Medline].
|
| 22. | Lion, T., and O. A. Haas. 1990. Nonradioactive labeling of probe with digoxigenin by polymerase chain reaction. Anal. Biochem. 188:335-337[Medline]. |
| 23. | McConville, M. L., and H. P. Charles. 1979. Mutants of Escherichia coli K12 permeable to haemin. J. Gen. Microbiol. 113:165-168[Medline]. |
| 24. | McConville, M. L., and H. P. Charles. 1979. Isolation of haemin-requiring mutants of Escherichia coli K12. J. Gen. Microbiol. 113:155-164[Medline]. |
| 25. | Mowjood, M., F. E. Miller, J. Schor, and F. E. Kocka. 1979. Small-colony forms of enteric bacteria after exposure to aminoglycosides. Am. J. Clin. Pathol. 72:79-81[Medline]. |
| 26. | Musher, D. M., R. E. Baughn, and G. L. Merrell. 1979. Selection of small-colony variants of Enterobacteriaceae by in vitro exposure to aminoglycosides: pathogenicity for experimental animals. J. Infect. Dis. 140:209-214[Medline]. |
| 27. | Musher, D. M., R. E. Baughn, G. B. Templeton, and J. N. Minuth. 1977. Emergence of variant forms of Staphylococcus aureus after exposure to gentamicin and infectivity of the variants in experimental animals. J. Infect. Dis. 136:360-369[Medline]. |
| 28. | Proctor, R. A. 1994. Microbial pathogenic factors: small colony variants, p. 79-90. In A. L. Bisno, and F. A. Waldvogel (ed.), Infections associated with indwelling medical devices. American Society for Microbiology, Washington, D.C. |
| 29. | Proctor, R. A., P. van Langevelde, M. Kristjansson, J. N. Maslow, and R. D. Arbeit. 1995. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin. Infect. Dis. 20:95-102[Medline]. |
| 30. | Roggenkamp, A., K. Ruckdeschel, L. Leitritz, R. Schmitt, and J. Heesemann. 1996. Deletion of amino acids 29 to 81 in adhesion protein YadA of Yersinia enterocolitica serotype O:8 results in selective abrogation of adherence to neutrophils. Infect. Immun. 64:2506-2514[Abstract]. |
| 31. | Rusthoven, J. J., T. A. Davies, and S. A. Lerner. 1979. Clinical isolation and characterization of aminoglycoside-resistant small colony variants of Enterobacter aerogenes. Am. J. Med. 67:702-706[Medline]. |
| 32. |
Sasarman, A.,
K. E. Sanderson,
M. Surdeanu, and S. Sonea.
1970.
Hemin-deficient mutants of Salmonella typhimurium.
J. Bacteriol.
102:531-536 |
| 33. | Sasarman, A., M. Surdeanu, V. Portelance, R. Dobardzic, and S. Sonea. 1971. Classification of vitamin K-deficient mutants of Staphylococcus aureus. J. Gen. Microbiol. 65:125-130[Medline]. |
| 34. |
Sasarman, A.,
M. Surdeanu,
G. Szegli,
T. Horodniceanu,
V. Greceanu, and A. Dumitrescu.
1968.
Hemin-deficient mutants of Escherichia coli K-12.
J. Bacteriol.
96:570-572 |
| 35. |
Sompolinsky, D.,
M. Cohen, and G. Ziv.
1974.
Epidemiological and biochemical studies on thiamine-less dwarf-colony variants of Staphylococcus aureus as etiological agents of bovine mastitis.
Infect. Immun.
9:217-228 |
| 36. |
Wilson, S. G., and C. C. Sanders.
1976.
Selection and characterization of strains of Staphylococcus aureus displaying unusual resistance to aminoglycosides.
Antimicrob. Agents Chemother.
10:519-525 |
| 37. | Wise, R. I. 1998. Small colonies (G variants) of staphylococci: isolation from cultures and infection. Ann. N. Y. Acad. Sci. 65:169-174. |
| 38. |
Yegian, D.,
G. Gallo, and M. W. Toll.
1959.
Kanamycin resistant Staphylococcus mutant requiring heme for growth.
J. Bacteriol.
78:10-12 |
| 39. | Youmans, G. P. 1937. Production of small colony variants of Staphylococcus aureus. Proc. Soc. Exp. Biol. Med. 36:94-98. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|